© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Breast Cancer
Addressing the Mechanism of Action for the AKT Pathway in TNBC
May 26, 2020
Rebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.
Entinostat Combo Fails to Meet End Point in Phase 3 HR+/HER2– Breast Cancer Study
May 26, 2020
Entinostat plus exemestame did not improve overall survival in patients with hormone receptor–positive, HER2-negative breast cancer.
Sacituzumab Govitecan Brings Long-Awaited Progress in the Treatment Landscape of mTNBC
May 25, 2020
In an interview with Targeted Oncology following the announcement of sacituzumab govitecan accelerated FDA approval, Hope Rugo, MD, discussed the published data from the phase 1/2 basket trial and the relevance of having sacituzumab govitecan available for the treatment of patients with metastatic triple negative breast cancer.
Older Patients With Triple-Negative Breast Cancer Should Be Assessed Different for Treatment
May 22, 2020
Enrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.
Neoadjuvant Durvalumab Regimen Improves Responses in Triple-Negative Breast Cancer
May 21, 2020
In an interview with Targeted Oncology, Lajos Pusztai, MD, DPhil, discussed the findings from the phase I/II clinical trial of durvalumab in combination with concurrent nab-paclitaxel and doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with triple-negative breast cancer.
First Trial of Immunotherapy in Early-Stage Triple-Negative Breast Cancer Shows Promising Results
May 18, 2020
In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the findings from the interim analysis for the phase III KEYNOTE-522 study, which added pembrolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer.
Insulin Resistance Plays Role in Racial Disparities in Breast Cancer Prognosis
May 14, 2020
“Our results raise a number of questions for future research and patient care. It will be important in future studies to explore whether lowering insulin levels or targeting IR signaling will improve breast cancer disparities."
Improving Upon Treatment Standards in HR+ Breast Cancer
May 11, 2020
In an interview with Targeted Oncology, Erica Mayer, MD, discussed advances in the treatment landscape of HR-positive, HER2-negative breast, primarily with endocrine therapy and CDK4/6 inhibition.
Endoxifen Uses Window-of-Opportunity to Reduce Tumor Activity in Breast Cancer
May 07, 2020
Administering endoxifen in the window of opportunity between diagnosis and treatment may be effective for reducing tumor activity in patients with breast cancer.
Antibody Drug Conjugate Sacituzumab Govitecan Shows Efficacy in TNBC
May 06, 2020
Aditya Bardia, MD, MPH, discusses the efficacy of sacituzumab govitecan in patients with triple-negative breast cancer.